Background and Aims: periprosthetic bone loss, especially in the proximal part of the femur, is common after cemented and uncemented total hip arthroplasty (thA). shortterm studies suggest that bisphosponates can minimize this bone loss related to stressshielding phenomenon. the aim of the present randomized study was to investigate whether the positive effect of a 6 months alendronate treatment postoperatively still exists at five-year follow up.
INTRODUCTION
Poor bone quality is a significant risk factor for complications in total hip arthroplasty (THA). Bone loss may threaten survival of function, and problems such as fractures of femoral bone or loosening of prostheses may occur (1, 2). Periprosthetic bone loss is found after both uncemented and cemented THA. After inserting the prosthesis, redistribution of load takes place and the stress on the proximal femur is reduced as the body weight shifts distally. The lack of load due to stress shielding induces bone resorption according to Wolff's law. Such bone loss takes place especially in the proximal femur (3-5). Bobyn et al. (3) found that the periprosthetic bone resorption is more pronounced with large stems and stems with extensive porous coating. To avoid the bone resorption, bending stiffness of the implant should be less than that of the femoral bone. Limited postoperative weight bearing and aseptic loosening have also roles in the periprosthetic bone loss (6).
With the dual energy X-ray absorptiometry (DXA), even the smallest changes in the density of bone adjacent to the metallic implant can be accurately measured. DXA has been accepted as a precise method to follow periprosthetic bone mineral density (BMD) postoperatively. Periprosthetic BMD decreases most rapidly during the first 3 to 6 months after THA. After the instant period of rapid loss, a plateau stage is reached during the first year after surgery, and BMD changes are minimal during the next few years (7-15). DXA studies have also shown that the patients with low preoperative BMD seem to have the greatest bone loss after THA (10, 15, 16) .
The positive effects of bisphosphonates on bone are well documented. These osteoactive drugs decrease the bone loss and can even increase the bone mass in postmenopausal women with or without osteoporosis (16) (17) (18) (19) (20) (21) . Two recent meta-analyses (21, 22) showed that the daily 10 mg alendronate administration to postmenopausal women with osteoporosis, it significantly and progressively increased bone mass at the lumbar spine, hip and total body during a 10-year follow-up. Meta-analyses also suggest that the postmenopausal women treated with alendronate have a decreased risk of several types of fractures including hip fractures. This continuous daily dose was well tolerated and no significant benefit was found using a higher dosage (19) .
Effects of bisphosphonates on the periprosthetic bone loss after primary THA have not been widely studied. We have previously shown in a 6 month´s prospective randomized study that alendronate therapy significantly reduces periprosthetic bone loss after primary THA, as compared with the changes found in patients without therapy (23) , Further Arabmotlagh et al. (24) found in their 6 months randomized double-blind study that the bone loss in proximal medial region was lower in alendronate treated THA patients compared to placebo (10% vs. 26%). These data suggest that alendronate administered for the first 6 postoperative months following THA was effective in preventing early periprosthetic bone loss. Bisphosphonates also sustain their therapeutic effects after discontinuation of the drug. A recent study showed that alendronate prevented fractures for a five year period after stopping the drug (21) .
To our knowledge, there are only two published long-term follow-up studies have investigated the effects of bisphosphonates on periprosthetic bone loss after primary THA (25, 26) . Therefore we conducted a randomized prospective trial to evaluate the efficacy of alendronate in long-term follow-up after uncemented THA.
MATERIALS AND METHODS
Sixteen patients participated in this prospective randomized controlled study. The study protocol was approved by the Ethics committee of Kuopio University's Hospital and the patients provided a written informed consent. For inclusion to in this study, the patients neither suffered from any diseases affecting bone metabolism nor used any bone-inducing medication previously. Moreover, the patients understood not to use other bone growth-inducing medication during the study. The patients also had to be able to comply with a standard postoperative mobilization schedule.
By using standard operative techniques in Kuopio University Hospital the patients were operated during the period from May, 1998 to October, 1999. Uncemented THA was performed using a hydroxyapatite-covered femoral stem and hydroxyapatite-coated cup (Omnifit; Osteonics, Stryker Howmedica, Allendale, NJ, USA). The indication for arthroplasty was primary hip osteoarthrosis in 15 patients. One patient was operated on to treat mild congenital luxation of the hip and acetabular dysplasia. Full weight bearing was allowed immediately after THA. However, all patients used crutches for 3 to 6 weeks after surgery.
The patients were randomized into two study groups for a 5-year follow-up period. Nine (five men and four women) received only 500 mg calcium carbonate (Calcichew; Nycomed Pharma, Oslo, Norway) daily. Seven (two men and five women) received 10 mg alendronate sodium (Fosamax; Merck, B. V. Haarlem, The Netherlands) supplemented by 500 mg calcium carbonate daily. Alendronate tablets were administrated orally 30 minutes before the breakfast, beginning the first day after surgery. The duration of the treatment was 6 months.
The mean age of the subjects was 58.9 years in the calcium-only group (range, 46 to 70 years) and 64.7 years in the alendronate-treated group (range, 59 to 71 years). All women were postmenopausal. The mean body mass index (BMI) was 27.8 kg/m 2 in the calcium-only group (range, 22.3 to 44.3 kg/m 2 ) and 28.5 kg/m 2 in the alendronatetreated group (range, 23.0 to 36.2 kg/m 2 ) ( Table 1) .
Periprosthetic BMD was measured using the Lunar DPX or Lunar DPX-IQ dual energy X-ray absorptiometry (DXA) instruments (Lunar Corp., Madison, WI, USA). Although two different pencil-beam DXA-models were in use, importantly, the measurements for each patient were performed using the same machine during the follow-up. The measurements were all done with no knowledge of the patients' treatment protocol. During scanning, the patient was placed in the supine position on the scan table. In each scan the femur was kept in neutral rotation using the standard knee and foot supports to minimize the measurement errors. The scan window included soft tissues, bone and the metallic implant. The special orthopaedic software in use, versions 1.2 and 4.6d (Lunar Corp.), automatically excluded soft tissues and the metallic implant from the analyses. Bone mineral content (BMC, g), areas (cm 2 ), and BMD (g/cm 2 ) were determined from seven regions of inter-est (ROIs; zones 1 through 7) based on Gruen zones (35). In addition, zones 1 through 7 were combined to represent the total ROI measurement (totROI), and zones 1 and 7 were combined to represent the proximal femoral ROI measurement (prROI) (10) .
Postoperative BMD measurements were made within two weeks of THA, i.e. at time it was possible to achieve optimal positioning of the hip, and subsequently at 3, 6, 12, 24, 36 and 60 months (the mean follow-up time was 59,6 months, SD 2,4 months). Clinical and radiological evaluations were made at each visit, and any adverse events were registered.
Postoperative BMD changes were normalized by using the immediate postoperative BMD as a reference value. Any change was expressed as a percentage (%). In the statistical analysis, we used SPSS software, version 14.0 (SPSS Inc., Chicago, IL, USA). Friedman's test was used to test whether BMD changes were significant during follow-up within the groups; Mann-Whitney and X2 tests were used to test for the differences between the groups. The linear correlations of the periprosthetic BMD change with selected factors were also studied. All tests were 2-tailed, using a critical p value of 0.05.
RESULTS
There were no postoperative complications during the follow-up, and no adverse events caused by the drugs were reported. No radiographic evidence of aseptic loosening was seen in any of the patients during the follow-up.
There were no significant differences in age, BMI or sex distribution between the groups. The immediate postoperative BMDs were not significantly different between the study groups (Table 1) .
During the 5 years of follow-up, the calcium-only group showed BMD variations from a 48.4% decrease to a 1.9% increase. In the alendronate-treated group, the BMD changes varied from a 13.7% decrease to 7.9% increase. In the calcium group, the mean 5 -year BMD decrease was 23.1% (SD 14.6) in BMD for prROI and 9.6% (SD 14.9) for totROI at the end of follow-up. In the alendronate group the decreases were smaller, 13.6% (SD 19.0) and 3.9% (SD 7.6) respectively (Table 2 and 3 and Fig. 1 and 2) . However, the changes between the study groups were not statistically different (Mann-Whitney test; Table 2 and 3 and Fig. 1 and  2 ). There was a significant change between groups up to 6 months of follow up, but subsequently the bone loss rates were quite similar.
We also studied the influence of patients' age, BMI and stem size on periprosthetic BMD changes. No significant correlations were found.
DISCUSSION
To our knowledge, this is one of the first studies in which the effect of bisphosphonate on the periprosthetic bone loss after THA has been followed-up for five years. Most of the previous bisphosphonate stud- (25) showed that, in comparison to the placebo, a single dose of 90 mg pamindronate produced no significant long term differences as measured by clinical or radiological methods. The periprosthetic bone loss is well documented in many studies (9) (10) (11) (12) (13) (14) . Previous studies have shown that the most significant bone loss occurs during the first 3 to 6 months after THA. In the proximal part of the femur, where the maximal bone resorption is expected, bone loss has varied from 16% to 30% depending on the study design, setting and implant used. After this rapid period, periprosthetic bone sta- The changes between the study groups are not significant after 60 months follow-up time. bilizes over the first postoperative year (8, [12] [13] [14] . The patients with low preoperative BMD have a tendency to loose more bone around the prosthesis (10, (13) (14) (15) . The rapid bone loss after THA is thought to arise from the phenomenon known as stress shielding. Loading on the proximal part of femur is bypassed after insertion of the prosthesis. It is unknown what is the long-term significance of stress shielding. Although the stress-shielding is common, it has not been shown to be an important mode of failure after cementless THA, including stems that generate large degrees of stress-shielding, out to the end of the second decade. However, in a recent study, in which bone densities of 127 patients were analysed after cemented THA, aseptic loosening, the most common cause for revision hip arthroplasty, was associated with poor bone quality (29) . The authors suggested that the patients with poor bone quality should have regular radiological follow-up and these patients may need some drug therapy to prevent aseptic loosening.
In the present study alendronate was administered 6-months period after THA. Despite of the cessation of drug administration at 6 months postoperatively the mean periprosthetic bone density was still a bit higher in bisphosphonate treated THA patients after the 5 year's follow-up as compared to calcium group. Although the differences between the groups did not reach statistical significance, a trend for positive alendronate effect could be suggested., Our study is partly in agreement with Arabmotlagh et al. who demonstrated the long-standing effect of alendronate in their 6-year follow-up study (26) . Shetty and coworkers studied patients with cemented femoral stems treated with a single dose of pamidronate or placebo, and could not find long-term differences between the groups. We along with Arabmotlagh et al.used aledronate in patients with uncemented femoral stems. As the bone loss rates in our study were quite similar in treatment groups after 6 months, the positive effect of alendronate on bone loss seems to take place during the early postoperative period. The total bone loss between groups at the end of the 5-year follow-up was not statistically different, so the clinical significance of our results remains unclear. To our knowledge no data has indicated that with high BMD the aseptic loosening could be thoroughly prevented.
We suggest that some patients may benefit from a short period of bisphosphonate administration after THA. The six months administration of alendronate seems to be long enough to prevent early periprosthetic bone loss. However, we could not show statistically significant long-term effect, probably due to insufficient statistical power. Alendronate is well tolerated and rapidly increases BMD in osteoporotic patients. Colón-Emeric et al. (27) found that alendronate, at a daily dose of 10mg, increased BMD remarkably and rapidly in the lumbar spine and other sites in the skeleton. Bone et al. (21) discovered that the therapeutic effects of alendronate were sustained after a five-year follow-up time in postmenopausal, osteoporotic women and the drug was well tolerated.
Similarly, our study suggests that 6 month´s alendronate treatment immediately after THA may have some positive long term net effect on the periprosthetic bone. The safety of this drug and cost-benefit of the treatment must be critically evaluated when using it generally for this indication.
The limitations of the present study include a low number of the patients. Therefore we used nonparametric test designed for small sample sizes. The insufficient statistical power relate to the small number of patients. There were some imbalance in age and gender between the groups, however, we suggest that it does not distort the results away from an alendronate effect. We did not measure the preoperative BMD. We, along with Nishii et al. (10, 14, 23) have shown that the best way to compare long-term BMD changes is to use the immediate postoperative value as a baseline value (8). Due to small number of cases, our study must still be regarded as a pilot study.
In conclusion, alendronate seems to decrerase early periprosthetic bone loss after arthroplasty but this pilot study could not provide enough evidence that the positive effect noted in the early postoperative period is still maintained 5 years after the operation. As, 5 years is still a short time when considering the hip implant survival, larger trials are needed to confirm the outcome of THA patients treated with alendronate.
